Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 15, Issue 5, 2015, Pages 565-580

  Drolet, Mélanie ^a,b   Bénard, Élodie ^a,b   Boily, Marie Claude ^a,b,c   Ali, Hammad ^d   Baandrup, Louise ^e   Bauer, Heidi ^f   Beddows, Simon ^g   Brisson, Jacques ^a,b   Brotherton, Julia M L ^h,i   Cummings, Teresa ^k   Donovan, Basil ^d   Fairley, Christopher K ^l,m   Flagg, Elaine W ⁿ   Johnson, Anne M ^o   Kahn, Jessica A ^p   Kavanagh, Kimberley ^q   Kjaer, Susanne K ^e,r   Kliewer, Erich V ^s,t,u   Lemieux Mellouki, Philippe ^a,b   Markowitz, Lauri ⁿ   Mboup, Aminata ^a   Mesher, David ^g   Niccolai, Linda ^v   Oliphant, Jeannie ^w   Pollock, Kevin G ^x   Soldan, Kate ^g   Sonnenberg, Pam ^o   Tabrizi, Sepehr N ^j,y,z   Tanton, Clare ^o   Brisson, Marc ^a,b,c   more..

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h VICTORIAN CYTOLOGY SERVICE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^m MONASH UNIVERSITY   (Australia)

ⁿ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^q UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^r UNIVERSITY OF COPENHAGEN   (Denmark)

^s UNIVERSITY OF MANITOBA   (Canada)

^t BRITISH COLUMBIA CANCER AGENCY   (Canada)

^u CANCERCARE MANITOBA   (Canada)

^v YALE UNIVERSITY   (United States)

^w Auckland Sexual Health Service   (New Zealand)

^x HEALTH PROTECTION SCOTLAND   (United Kingdom)

^y ROYAL WOMEN'S HOSPITAL   (Australia)

^z MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; CROSS PROTECTION; HERD; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; META ANALYSIS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; ECONOMICS; FEMALE; IMMUNOLOGY; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PATHOLOGY; PREVENTIVE HEALTH SERVICE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; CROSS PROTECTION; DEVELOPED COUNTRIES; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84928216017     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71073-4     Document Type: Article

References (75)

1. Countries with HPV vaccine in the national immunization programme and planned introductions. World Health Organization/IVB Database WHO, (accessed Sept 15, 2014). http://www.who.int/immunization/diseases/hpv/decision_implementation/en/.
2. Progress in cervical cancer prevention. The CCA report card Cervical Cancer Action (CCA), (accessed Sept 15, 2014). http://www.cervicalcanceraction.org/pubs/CCA_reportcard_low-res.pdf.
3. Countries and economies The World Bank, (accessed Sept 15, 2014). http://data.worldbank.org/country.
4. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health 2014, 14:670.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
6. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
7. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(suppl 5):F139-F148.
8. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1705-1708. Centers for Disease Control and Prevention.
9. Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012, 12:627-634.
10. Paul P, Fabio A Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine 2014, 32:320-326.
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
12. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
13. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
14. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
15. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
16. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
17. Brisson M, Van de Velde N, Boily MC Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
18. Fesenfeld M, Hutubessy R, Jit M Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine 2013, 31:3786-3804.
19. Jit M, Brisson M, Portnoy A, Hutubessy R Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014, 2:e406-e414.
20. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104:1712-1723.
21. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204:372-376.
22. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28:4091-4102.
23. Baussano I, Dillner J, Lazzarato F, Ronco G, Franceschi S Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agent Cancer 2014, 9:4.
24. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 2011, 8:e1001147.
25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
26. Rosner B Fundamentals of biostatistics 1995, Wadsworth Publishing Company, Belmont. 4th edn.
27. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
28. Deeks JJ, Higgins PT Statistical algorithms in Review Manager 5 (accessed May 28, 2014). http://www.cochrane.org/sites/default/files/uploads/handbook/Statistical_Methods_in_RevMan5-1.pdf.
29. Cochrane handbook for systematic reviews of interventions, version 5.1.0 2011, The Cochrane Collaboration, (accessed May 28, 2014). http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
30. Berlin JA, Longnecker MP, Greenland S Meta-analysis of epidemiologic dose-response data. Epidemiology 1993, 4:218-228.
31. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012, 30:5496-5499.
32. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130:e249-e256.
33. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651.
34. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208:385-393.
35. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013, 32:26-32.
36. Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013, 382:1795-1806.
37. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014, 110:2804-2811.
38. Oliphant J, Perkins N Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011, 124:51-58.
39. Bauer HM, Wright G, Chow J Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102:833-885.
40. Kliewer E, Mahmud SM, Demers AA, Lambert P, Musto G. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada. 28th International Papillomavirus Conference; San Juan, Puerto Rico; Nov 30-Dec 6, 2012. Abstract E07-663.
41. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206:860-866.
42. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
43. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013, 40:130-135.
44. Howell-Jones R, Soldan K, Wetten S, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013, 208:1397-1403.
45. Flagg EW, Schwartz R, Weinstock H Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013, 103:1428-1435.
46. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013, 40:28-31.
47. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013, 20:17-20.
48. Sando N, Kofoed K, Zachariae C, Fouchard J A reduced national incidence of anogenital warts in young Danish Men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women-an ecological study. Acta Derm Venereol 2014, 94:288-292.
49. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
50. Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013, 22:1446-1450.
51. Cervical screening in Australia 2010-2011. National Cervical Screening Program. AIHW Cancer series no. 76 Australian Institute of Health and Welfare, (accessed June 4, 2014). http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129543399.
52. National Health And Nutrition Examination Survey: Analytic Guidelines, 1999-2010. Data evaluation and methods research. Series 2, number 161 US Department of Health and Human Services, Centers for Disease Control and PreventionCenters for Disease Control and Prevention, (accessed July 17, 2014). http://www.cdc.gov/nchs/data/series/sr_02/sr02_161.pdf.
53. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
54. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013, 105:469-474.
55. Blomberg M, Dehlendorff C, Munk C, Kjaer SK Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013, 57:929-934.
56. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11:227.
57. Mercer CH, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013, 382:1781-1794.
58. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006, 368:1706-1728.
59. Mori S, Nakao S, Kukimoto I, Kusumoto-Matsuo R, Kondo K, Kanda T Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011, 102:1223-1227.
60. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014, 10:2147-2162.
61. Pagliusi SR, Teresa Aguado M Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004, 23:569-578.
62. Statement on human papillomavirus vaccine. Canada Communicable Disease Report, volume 33 National Advisory Committee on Immunization (NACI), (accessed June 15, 2014). http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-02/index-eng.php.
63. Clinical review-human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant-Gardasil US Food and Drug Administration, (accessed June 15, 2014). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111287.pdf.
64. Guidance for the introduction of HPV vaccines in EU countries European Centre for Disease Prevention and Control, (accessed June 15, 2014). http://www.ecdc.europa.eu/en/Documents/4940_0801_HPV_guidance.pdf.
65. Steens A, Wielders CC, Bogaards JA, Boshuizen HC, de Greeff SC, de Melker HE Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention. Int J Cancer 2013, 132:932-943.
66. Kliewer EV, Mahmud SM, Demers AA, Lambert P Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. Vaccine 2013, 32:33-38.
67. Spencer AM, Roberts SA, Brabin L, Patnick J, Verma A Sociodemographic factors predicting mother's cervical screening and daughter's HPV vaccination uptake. J Epidemiol Community Health 2014, 68:571-577.
68. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013, 105:175-201.
69. Brisson M, Van de Velde N, Boily MC Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect 2011, 87:41-43.
70. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
71. Clifford GM, Smith JS, Aguado T, Franceschi S Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
72. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
73. Globocan 2008. Cervical cancer incidence and mortality worldwide 2008 International Agency for Research on Cancer, (accessed May 14, 2012). http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
74. Adler DH, Kakinami L, Modisenyane T, et al. Increased regression and decreased incidence of HPV-related cervical lesions among HIV-infected women on HAART. AIDS 2012, 26:1645-1652.
75. Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013, 31:5745-5753.